ImaginAb and Cyclotek Enter into Manufacturing and Distribution Agreement for CD8 ImmunoPET Agent in Australia
prnewswire.com
news
2022-10-17 07:00:00

INGLEWOOD, Calif., Oct. 17, 2022 /PRNewswire/ -- ImaginAb, Inc., a global biotechnology company focused on developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET) imaging agent and radiopharmaceutical therapies (RPT) products, is pleased to announce the completion of a Master Services Agreement with Cyclotek, a leading radiopharmaceutical manufacturer in Australia and New Zealand, for the commercial manufacturing and distribution of its investigational CD8 ImmunoPET agent in Australia.Â 
Under the terms of the agreement, Cyclotek will initially supply patient-specific unit doses of the imaging agent from its Melbourne-based radiopharmacy to clinical sites across Australia, for ImaginAb's clinical trials and the clinical sites for immunotherapy studies sponsored by pharma and biotech companies that have licensed CD8 ImmunoPET.
